Heska Corporation to Present at the Raymond James Annual Institutional Investors Conference

LOVELAND, Colo., Feb. 18, 2020 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska's President & Chief Executive Officer, will present at the Raymond James 41st Annual Institutional Investors Conference on Tuesday, March 3, 2020 at 9:50 a.m. ET in Orlando, FL.

Heska Corporation (PRNewsfoto/Heska Corporation)

Mr. Wilson will also be available for one-on-one meetings on March 3rd. To schedule a meeting, please contact Raymond James at corporateaccess@raymondjames.com or Heska Investor Relations at investorrelations@heska.com.

A live webcast of the company's presentation can be accessed at http://wsw.com/webcast/rj119/hska/.

The webcast will be archived shortly after the event, and a replay will be available on the company's website for 90 days following the conference. A copy of the presentation will be available on Heska's website at https://ir.heska.com/event/presentation/.

For more information about the Raymond James Annual Institutional Investors Conference, visit: https://www.raymondjames.com/corporations-and-institutions/global-equities-and-investment-banking/conferences-and-events.

About Heska
Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through two business segments. The Core Companion Animal Health ("CCA") segment represents approximately 85% of revenues, and the Other Vaccines and Pharmaceuticals ("OVP") segment represents approximately 15% of revenues, as of September 30, 2019. CCA segment includes Point of Care Laboratory testing instruments and consumables, primarily under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP segment includes private label vaccine and pharmaceutical production under third party agreements and channels, primarily for herd animal health.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/heska-corporation-to-present-at-the-raymond-james-annual-institutional-investors-conference-301006120.html

SOURCE Heska Corporation


Back to news